Skip to main content
. Author manuscript; available in PMC: 2021 Jan 21.
Published in final edited form as: Sci Transl Med. 2020 Jun 24;12(549):eaay6570. doi: 10.1126/scitranslmed.aay6570

Fig. 4. Meta-analysis of BMD-increasing SOST variants and cardiometabolic risk factors.

Fig. 4

(A) Association with hypertension and T2D. (B) Association with quantitative traits plotted in SD units, with clinical units for each trait indicated in the column on the right. All estimates are scaled to match the effect of romosozumab (210 mg monthly for 12 months) on LS-BMD (0.09 g/cm2; see Materials and Methods) and aligned to the BMD-increasing alleles. The significance threshold was set at 0.004 (see Materials and Methods for details). Boxes represent point estimates of effects in OR (A) or SD (B) units. Lines represent 95% CIs. U, units.